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Purpose of the study
Fos-Amprenavir is one of the protease inhibitor that is
recommended to treat protease inhibitor naïve of
experienced patients. Amprenavir and darunavir share at
least in part chemical structures and thus a possible
selection of close protease gene mutations. Little is
known about the frequency and the type of resistance
mutations selected after virological failure to Fos-
Amprenavir containing regimen. The aim of this study
was to determine the genetic patterns and the preva-
lence of resistance mutations associated to virological
failure to Fos-Amprenavir containing regimens in a
cohort of naïve and experienced protease inhibitor
patients.
Methods
172 PI experienced patients, treated by r/Fos-APV (100/
700 mg BID) and 96 PI naïve patients treated by r/Fos-
APV (100/700 mg BID n = 33 and 100/1400 mg OD n
= 63) were analyzed. Reverse transcriptase (RT) and
protease gene were sequenced and aminoacid changes
analyzed before Fos-APV treatment and at time of viro-
logical failure. Mutations were analyzed with the ANRS
algorithm V18.
Summary of results
In PI experienced patients, there is a direct link between
the number of PI resistance that were present at base-
line and the probability of selection of resistance muta-
tion at failure (p=0.01). The most common mutations
selected were: V32I, L33F, M46L, I50V, I54L/V, I84V
and L90M. In all cases when the protease gene at
baseline harbored at least one PI resistance mutation, at
least one resistance mutation was added at time of viro-
logical failure. Taking into account of the ANRS algo-
rithm, 15% of patient developed a resistance to DRV. In
PI naïve patients, only 6% of patients harbored a PI
resistance mutation selected at time of virological fail-
ure. The most frequent selected mutations were V32I,
I47V, I50V and I84V. There is a link between the dura-
tion of virological failure under r/Fos-APV and the rate
of selected mutation (1% of cases at month 1, 3% at
month 3 and 6% at month 6. Taking into account of the
ANRS algorithm, only one patient developed a resis-
tance to DRV.
Conclusions
This study confirms that resistance mutations selected
by Fos-APV occurs mainly in PI experienced patients.
Except for patients with more than 6 months replication
with Fos-APV, the risk to select cross resistance to DRV
is very low.
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